Stockholm, 4 December, 2025 – ScandiBio Therapeutics AB today announced that the first 100 patients have been recruited to the multi-centre, phase 3 human clinical trial…
Alzheimer’s disease (AD) is the most common cause of dementia, which is a general term for memory loss and other cognitive impairments that are significant enough…
A phase-2 human clinical study showed that patients with nonalcoholic fatty liver disease (NAFLD) experienced a significant reduction in liver fat when receiving the combination of…
ScandiBio Therapeutics announced Phase 2 clinical trial results from the study on the open-access server medRxiv.org. The results: Combined Metabolic Activators Improve Cognitive Functions without Altering…
ScandiBio Therapeutics announced Phase 2 clinical trial results from the study on the open-access server medRxiv.org. The study: Combined Metabolic Activators Improves Cognitive Functions in Alzheimer’s…
The results of a Phase I study have been published in the journal Molecular Systems Biology describing the kinetics of the Combined Metabolic Cofactor Supplementation (CMCS)…
The Swedish biotechnology company ScandiBio Therapeutics today announced results from the study. The study conducted in Turkey was published on February 20 on medRxiv, a preprint…
ScandiBio Therapeutics announced results from the study “Combined Metabolic Activators Reduces Liver Fat in Nonalcoholic Fatty Liver Disease” were published on Cell Press Sneak Peek, a…
ScandiBio Therapeutics has completed a Phase II study based on treatment of patients with COVID-19. Patients with mild-to-moderate COVID-19 experienced a 29% reduction in recovery time…
ScandiBio Therapeutics has initiated a Phase II study in patients with COVID-19 using Combined Metabolic Cofactors Supplementation (CMCS) consisting of L-serine, N-acetyl-L-cysteine (NAC), nicotinamide riboside (NR),…